

Stefani Spranger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8740072/publications.pdf>

Version: 2024-02-01

49
papers

12,565
citations

136940

32
h-index

254170

43
g-index

53
all docs

53
docs citations

53
times ranked

19264
citing authors

#	ARTICLE	IF	CITATIONS
1	Melanoma-intrinsic β -catenin signalling prevents anti-tumour immunity. <i>Nature</i> , 2015, 523, 231-235.	27.8	2,130
2	Up-Regulation of PD-L1, IDO, and T _{regs} in the Melanoma Tumor Microenvironment Is Driven by CD8 ⁺ T Cells. <i>Science Translational Medicine</i> , 2013, 5, 200ra116.	12.4	1,447
3	STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors. <i>Immunity</i> , 2014, 41, 830-842.	14.3	1,325
4	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	9.4	1,158
5	Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. <i>Cancer Cell</i> , 2017, 31, 711-723.e4.	16.8	1,011
6	Impact of oncogenic pathways on evasion of antitumour immune responses. <i>Nature Reviews Cancer</i> , 2018, 18, 139-147.	28.4	506
7	Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8 ⁺ T cells directly within the tumor microenvironment. , 2014, 2, 3.		460
8	WNT/ β -catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 3074-3083.	7.0	435
9	Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2013, 25, 268-276.	5.5	352
10	Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7759-E7768.	7.1	328
11	Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 563-568.	3.4	293
12	Innate immune signaling and regulation in cancer immunotherapy. <i>Cell Research</i> , 2017, 27, 96-108.	12.0	291
13	Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 5427-5433.	7.0	254
14	Increased demand for NAD ⁺ relative to ATP drives aerobic glycolysis. <i>Molecular Cell</i> , 2021, 81, 691-707.e6.	9.7	232
15	Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. <i>International Immunology</i> , 2016, 28, 383-391.	4.0	223
16	Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL. <i>Cancer Cell</i> , 2012, 22, 825-837.	16.8	216
17	WNT Signaling in Cancer Immunosurveillance. <i>Trends in Cell Biology</i> , 2019, 29, 44-65.	7.9	168
18	Lymphatic vessels regulate immune microenvironments in human and murine melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3389-3402.	8.2	157

#	ARTICLE	IF	CITATIONS
19	Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	141
20	Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. <i>Cancer Immunology Research</i> , 2018, 6, 14-24.	3.4	129
21	Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. <i>Immunity</i> , 2022, 55, 308-323.e9.	14.3	126
22	Tumor-intrinsic oncogene pathways mediating immune avoidance. <i>Oncot Immunology</i> , 2016, 5, e1086862.	4.6	120
23	Secondary resistance to immunotherapy associated with β -catenin pathway activation or PTEN loss in metastatic melanoma. , 2019, 7, 295.		98
24	MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. <i>Journal of Clinical Investigation</i> , 2010, 120, 3869-3877.	8.2	86
25	Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. <i>Molecular and Biochemical Parasitology</i> , 2009, 167, 54-59.	1.1	77
26	Direct and Indirect Regulators of Epithelialâ€“Mesenchymal Transitionâ€“Mediated Immunosuppression in Breast Carcinomas. <i>Cancer Discovery</i> , 2021, 11, 1286-1305.	9.4	76
27	Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. <i>Advances in Immunology</i> , 2016, 130, 75-93.	2.2	74
28	Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075. <i>Journal of Immunology</i> , 2010, 185, 738-747.	0.8	70
29	Mechanisms of Tumor Cellâ€“Intrinsic Immune Evasion. <i>Annual Review of Cancer Biology</i> , 2018, 2, 213-228.	4.5	65
30	Lack of CD8 ⁺ T cell effector differentiation during priming mediates checkpoint blockade resistance in nonâ€“small cell lung cancer. <i>Science Immunology</i> , 2021, 6, eabi8800.	11.9	58
31	TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. <i>Blood</i> , 2012, 119, 3440-3449.	1.4	55
32	The CD6 Scavenger Receptor Is Differentially Expressed on a CD56 ⁺ Natural Killer Cell Subpopulation and Contributes to Natural Killer-Derived Cytokine and Chemokine Secretion. <i>Journal of Innate Immunity</i> , 2011, 3, 420-434.	3.8	44
33	Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling. <i>Journal of Cell Biology</i> , 2020, 219, .	5.2	42
34	Frontiers in cancer immunotherapyâ€“a symposium report. <i>Annals of the New York Academy of Sciences</i> , 2021, 1489, 30-47.	3.8	39
35	Deciphering the immunopeptidome in vivo reveals new tumour antigens. <i>Nature</i> , 2022, 607, 149-155.	27.8	38
36	Tissue Site and the Cancer Immunity Cycle. <i>Trends in Cancer</i> , 2019, 5, 593-603.	7.4	37

#	ARTICLE	IF	CITATIONS
37	Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras. <i>Cell Stem Cell</i> , 2020, 26, 579-592.e6.	11.1	32
38	Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. , 2021, 9, e002417.		21
39	Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. <i>Cell Reports</i> , 2021, 37, 110021.	6.4	21
40	A team effort: natural killer cells on the first leg of the tumor immunity relay race. , 2018, 6, 67.		20
41	Cutting Edge: Engineering Active IKK \hat{I}^2 in T Cells Drives Tumor Rejection. <i>Journal of Immunology</i> , 2016, 196, 2933-2938.	0.8	18
42	Tumor Heterogeneity and Tumor Immunity: A Chicken-and-Egg Problem. <i>Trends in Immunology</i> , 2016, 37, 349-351.	6.8	15
43	A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion. <i>Immunity</i> , 2018, 49, 11-13.	14.3	12
44	Impact of anatomic site on antigen-presenting cells in cancer. , 2020, 8, e001204.		10
45	MYC â€” a thorn in the side of cancer immunity. <i>Cell Research</i> , 2016, 26, 639-640.	12.0	7
46	CD36 â€” the Achillesâ€™ heel of Treg cells. <i>Nature Immunology</i> , 2020, 21, 251-253.	14.5	6
47	STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors. <i>Immunity</i> , 2015, 42, 199.	14.3	5
48	Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins. , 2022, 10, e004159.		5
49	The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 447-456.	2.6	2